Nvidia Partners With Fanuc and Yaskawa to Accelerate AI Robotics in Japan 
BHP Q4 Iron Ore Output Rebounds as Copper Prices Boost Revenue 
xAI Sues Man for Allegedly Using Grok to Generate AI Child Abuse Deepfakes 
Stripe, Advent Offer Over $53 Billion to Acquire PayPal in Major Fintech Deal 
ASML Raises 2026 Outlook as AI Chip Demand Lifts Q2 Earnings 
Jamie Dimon Warns Anthropic's Mythos AI Poses National Security Risks 
DBS Targets S$1 Trillion Wealth AUM by 2030 Amid Asia Wealth Boom 
DeepSeek Eyes China IPO as AI Startup Seeks $71 Billion Valuation in New Funding Round 
United Airlines Beats Q2 Earnings, Raises 2026 Profit Outlook Despite Higher Fuel Costs 
Airbus Signs Cloud Deal With Scaleway to Power Secure AI and Defense Applications 
Arm Stock Falls After HSBC Downgrade, Citing Limited Near-Term AI Upside 
Rio Tinto Reports Strong Q2 Iron Ore Sales, Maintains 2026 Production Outlook 
Eli Lilly Eyes AtaiBeckley Acquisition to Expand Psychedelic Mental Health Pipeline 
BHP Faces Major Port Hedland Strike as Labor Talks Stall Ahead of Production Report 
Yaskawa Electric Shares Slide as Weak Profit Overshadows Strong AI Demand 
SpaceX Stock Falls Below IPO Price as Investors Weigh Losses and Lockup Expiry 
Volkswagen Launches €28,000 ID. Cross EV as Europe’s Electric Vehicle Demand Accelerates 
SOUTH SAN FRANCISCO, Calif., Jan. 22, 2016 -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical stage biotechnology company focused on the development of novel cancer therapeutics, today announced that preclinical data for its lead immuno-oncology therapeutic candidate, CB-1158 has been selected for an oral presentation at the 2016 Keystone Symposia on Cancer Immunotherapy taking place January 24-28, 2016, in Vancouver, Canada. CB-1158 is a first-in-class immuno-oncology metabolic checkpoint inhibitor targeting arginase, a key immunosuppressive enzyme that limits T-cell proliferation in a wide range of tumors. Details for the presentation are as follows:
Arginase Inhibitor CB-1158 is a Novel Immuno-Oncology Agent that Targets Tumor-Infiltrating Suppressive Myeloid Cells
Date: January 27, 2016
Session: Novel Immunotherapeutic Approaches and Antibody Therapies
Time: 5:00 p.m. -7:00 p.m. PT
Presenter: Susanne Steggerda, Ph.D., Calithera Biosciences
Abstract #3014
Poster Display: 7:30 a.m. - 10:00 a.m. PT
About Calithera Biosciences
Calithera Biosciences, Inc. is a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. Calithera’s lead product candidate, CB-839, is currently being evaluated in three Phase 1 clinical trials in solid and hematological cancers. CB-1158 is a first-in- class immuno-oncology metabolic checkpoint inhibitor targeting arginase, a critical immunosuppressive enzyme responsible for T-cell suppression by myeloid-derived suppressor cells. Arginase depletes arginine, a nutrient that is critical for the activation, growth and survival of the body’s cancer-fighting immune cells, known as cytotoxic T -cells. Calithera is headquartered in South San Francisco, California. For more information about Calithera, please visit www.calithera.com.
CONTACT:
Jennifer McNealey
650-870-1071
